Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Tenon Medical’s SEC disclosures can feel like wading through surgical manuals—clinical trial data, FDA updates, and complex revenue notes often hide in 200-page documents. If you need Tenon Medical insider trading Form 4 transactions before the market reacts or want the story behind catheter-to-cash burn ratios, the raw forms alone won’t do.
Stock Titan solves that problem. Our AI deciphers every Tenon Medical quarterly earnings report 10-Q filing, highlights cash runway and Catamaran System adoption, and pushes real-time alerts for Tenon Medical Form 4 insider transactions real-time. Prefer plain English? Click “AI Summary” to see Tenon Medical SEC filings explained simply—from clinical-study milestones in an 8-K to reimbursement commentary buried in the MD&A.
Here’s how investors use it daily:
- Monitor surgeon-director buys with Tenon Medical executive stock transactions Form 4
- Compare R&D spend across quarters with our Tenon Medical earnings report filing analysis
- Spot pivotal trial results via Tenon Medical 8-K material events explained
- Review pay packages inside the Tenon Medical proxy statement executive compensation
- Dive deep with a Tenon Medical annual report 10-K simplified overview that links each risk factor to real-world impact
Every form—10-K, 10-Q, 8-K, S-1, or Section 16—lands here seconds after EDGAR posts. Our expert layer adds context so you can focus on decisions, not deciphering medical jargon. That’s understanding Tenon Medical SEC documents with AI.
Tenon Medical (TNON) reported Q3 results and completed two asset acquisitions to expand its SI joint portfolio. Revenue was $1.173 million versus $0.887 million a year ago, with gross margin improving to 66% from 47% as higher volumes reduced fixed production costs per unit. Net loss was $3.339 million compared with $3.184 million.
Cash and cash equivalents were $3.442 million as of September 30, 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern for one year after issuance, and plans to seek additional financing.
In August, Tenon acquired substantially all assets of SiVantage and SIMPL (treated as a single business combination) for total consideration of $3.127 million, including $0.75 million in cash, 710,300 shares, and contingent consideration; goodwill recorded was $2.407 million. As a subsequent event, the company announced a $2.85 million PIPE financing, issuing 2,217,904 common shares and warrants to purchase 2,217,904 shares at a combined price of $1.285 per share-and-warrant, with warrants exercisable at $1.16.
Shares outstanding were 8,605,740 as of November 13, 2025.
Tenon Medical, Inc. filed an Amendment No. 1 to Form 8-K to add required financial information related to its previously reported acquisition of substantially all assets of SiVantage, Inc. The amendment updates Item 9.01 to present the acquired business’s financial statements and the company’s unaudited pro forma financials.
Exhibit 99.1 includes SiVantage’s audited financial statements for the year ended December 31, 2024 and unaudited financial statements for the six months ended June 30, 2025. Exhibit 99.2 provides an unaudited pro forma condensed balance sheet as of June 30, 2025 and unaudited pro forma condensed statements of operations for the year ended December 31, 2024 and the six months ended June 30, 2025. The amendment does not otherwise modify or update the original report.
Tenon Medical, Inc. reported an unregistered issuance of 866,642 restricted stock units (RSUs) to its directors and officers under the company’s 2022 Equity Incentive Plan.
The RSUs vest in two equal tranches, with 50% on January 1, 2026 and 50% on July 31, 2026, and each RSU will convert into one share of common stock upon vesting. The issuance was made in reliance on Section 4(a)(2) of the Securities Act as a private offering.
Tenon Medical (TNON) reported a director equity award. Director Stephen Hochschuler received 21,464 restricted stock units (RSUs) on 10/13/2025 (Form 4, code A). Each RSU represents one share of common stock.
The grant vests in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026. The RSUs were reported at a price of $0 and are held directly.
Tenon Medical (TNON) filed a Form 4 reporting an equity award to a director. On 10/13/2025, the reporting person acquired 21,464 restricted stock units (RSUs), each representing the right to receive one share of common stock. The derivative security price is listed as $0.
According to the filing, vesting occurs in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. Following the transaction, 21,464 derivative securities are beneficially owned on a direct basis.
Tenon Medical (TNON) reported an insider equity grant. Director and Chief Technology Officer Richard Ginn received 253,153 restricted stock units (RSUs) on 10/13/2025. Each RSU represents the right to receive one share of common stock.
The RSUs vest in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026. The filing lists the derivative security price as $0 and indicates direct ownership following the transaction.
Tenon Medical (TNON) reported an insider equity grant on Form 4. Chief Financial Officer and Director Kevin Williamson was awarded 117,974 restricted stock units (RSUs) on 10/13/2025.
Each RSU represents the right to receive one share of common stock. The grant vests in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. Following the reported transaction, 117,974 derivative securities were beneficially owned, held directly.
Tenon Medical (TNON)281,872 restricted stock units on October 13, 2025. Each RSU represents the right to receive one share of Tenon common stock. The filing states a derivative security price of $0.
The award vests in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. The ownership reported for these derivative securities is Direct.
Tenon Medical (TNON) reported a director equity grant. On 10/13/2025, a director received 21,464 restricted stock units (RSUs) at a price of $0, as disclosed in a Form 4 filing.
Each RSU represents the right to receive one share of common stock. The vesting schedule splits evenly: 50% of the RSUs vest and convert into common stock on January 1, 2026, and the remaining 50% vest and convert on July 31, 2026. Following the grant, the reporting person held 21,464 derivative securities directly.
Tenon Medical (TNON) reported an insider equity award. A director received 20,293 restricted stock units (RSUs) on 10/13/2025, recorded at $0 as typical for RSU grants. Each RSU represents the right to receive one share of common stock.
The award vests in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026, after which the vested RSUs automatically convert into common shares on a one-for-one basis. Following the reported transaction, the director held 20,293 derivative securities directly.
FAQ
What is the current stock price of Tenon Medical (TNON)?
What is the market cap of Tenon Medical (TNON)?
